Publicacions en col·laboració amb investigadors/es de Hospital Virgen del Camino (55)

2023

  1. Generation of an induced pluripotent stem cell line (ESi107-A) from a transthyretin amyloid cardiomyopathy (ATTR-CM) patient carrying a p.Ser43Asn mutation in the TTR gene

    Stem Cell Research, Vol. 71

  2. Modulating T Cell Responses by Targeting CD3

    Cancers, Vol. 15, Núm. 4

  3. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823

2022

  1. A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression

    Molecular Therapy - Nucleic Acids, Vol. 29, pp. 413-425

  2. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  3. CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage

    Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325

  4. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    European Journal of Cancer, Vol. 174, pp. 243-250

  5. Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease

    European Journal of Vascular and Endovascular Surgery, Vol. 63, Núm. 4, pp. 648-656

  6. Neutrophil-to-lymphocyte ratio as a cardiovascular risk biomarker in psoriasis: A comprehensive review

    JEADV Clinical Practice, Vol. 1, Núm. 4, pp. 397-406

  7. Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System

    Biomedicines, Vol. 10, Núm. 8

2021

  1. Association of calprotectin with other inflammatory parameters in the prediction of mortality for ischemic stroke

    Journal of Neuroinflammation, Vol. 18, Núm. 1

  2. Association of sdf1 and mmp12 with atherosclerosis and inflammation: Clinical and experimental study

    Life, Vol. 11, Núm. 5

  3. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  4. Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients

    Transfusion and Apheresis Science, Vol. 60, Núm. 3

  5. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  6. Inside the Thrombus: Association of Hemostatic Parameters With Outcomes in Large Vessel Stroke Patients

    Frontiers in Neurology, Vol. 12

  7. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

  8. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

  9. The role of circulating biomarkers in peripheral arterial disease

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

  10. Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH)

    Clinical Transplantation, Vol. 35, Núm. 5